Efficacy and safety of a combined treatment schedule with fulvestrant (F) and capecitabine (C) in elderly advanced breast cancer patients

被引：0
|
作者：
Carreca, I.
Bellomo, F.
Brizzi, M.
Bronte, G.
Burgio, S.
Piazza, D.
Rizzo, S.
Russo, S.
Balducci, L.
机构：
[1] Univ Palermo, Palermo, Italy
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.12003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12003
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Fulvestrant and capecitabine in elderly advanced breast cancer patients: The proposal for an effective and safe combined treatment schedule
    Bronte, Giuseppe
    Bellomo, Fernanda
    Burgio, Marco
    Carreca, Annapaola
    Piazza, Dario
    Rizzo, Sergio
    Russo, Salvatore
    Carreca, Ignazio
    ANNALS OF ONCOLOGY, 2007, 18 : 49 - 49
  • [2] FULVESTRANT PLUS CAPECITABINE IN ELDERLY ADVANCED BREAST CANCER (EABC): A COMBINED TREATMENT AND 48 MONTHS OBSERVATION OF EFFICACY AND SAFETY
    Carreca, I.
    Antista, M.
    Bellomo, F.
    Pernice, G.
    ANNALS OF ONCOLOGY, 2011, 22 : 61 - 62
  • [3] A COMBINED TREATMENT SCHEDULE WITH FULVESTRANT (FLV) AND DOCETAXEL (TXT) IN ELDERLY ADVANCED BREAST CANCER (E- ABC) PATIENTS: FIRST RESULTS ABOUT SAFETY AND EFFICACY
    Russo, S.
    Piazza, D.
    Bellomo, F.
    Burgio, S.
    D'alia, P.
    Pernice, G.
    Semprevivo, M.
    Carreca, I
    ANNALS OF ONCOLOGY, 2009, 20
  • [4] Eribnlin (E) and capecitabine (C), a combined treatment schedule in elderly metastatic breast cancer (EMBC): Efficacy and safety evaluation (E&S)
    Carreca, Ignazio Ugo
    D'alia, Paolo
    Bronte, Giuseppe
    Bazan, Viviana
    Cova, Dario
    Foa, Paolo
    Russo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients
    T. Gamucci
    L. Moscetti
    L. Mentuccia
    L. Pizzuti
    M. Mauri
    G. Zampa
    I. Pavese
    I. Sperduti
    A. Vaccaro
    P. Vici
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 221 - 226
  • [6] Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients
    Gamucci, T.
    Moscetti, L.
    Mentuccia, L.
    Pizzuti, L.
    Mauri, M.
    Zampa, G.
    Pavese, I.
    Sperduti, I.
    Vaccaro, A.
    Vici, P.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (02) : 221 - 226
  • [7] Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity
    Ma, Y.
    Tang, L.
    Wang, H. -X.
    Xu, Y. -C.
    Ma, Y.
    Zhang, F. -C.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (03) : 266 - 275
  • [8] Fulvestrant for the treatment of advanced breast cancer
    Blackburn, Sophie A.
    Parks, Ruth M.
    Cheung, Kwok-Leung
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (07) : 619 - 628
  • [9] Efficacy and safety of apatinib combined with capecitabine in patients with advanced nasopharyngeal carcinoma
    Cai, X.
    Li, Z.
    Mai, H.
    Chen, Q.
    Zhao, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S672 - S672
  • [10] Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women
    Bajetta, E
    Procopio, G
    Celio, L
    Gattinoni, L
    Della Torre, S
    Mariani, L
    Catena, L
    Ricotta, R
    Longarini, R
    Zilembo, N
    Buzzoni, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2155 - 2161
12345